Federal Register / Vol. 63, No. 123 / Friday, June 26, 1998 / Notices 34901

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Announcement 98037]

Initiatives by Organizations To

Strengthen National Tobacco Control

Activities in the United States; Notice

of Availability of Funds for Fiscal Year

1998; Second Amendment

A notice announcing the availability

of Fiscal Year 1998 funds for

cooperative agreements for Initiatives by

Organizations to Strengthen National

Tobacco Control Activities in the United

States was published in the Federal

Register on April 23, 1998 [63 FR

20197]. The notice is amended as

follows:

On page 20197, first paragraph, under

the heading ‘‘Introduction,’’ the seventh

line of the paragraph is amended to

read:populations; African-Americans,

Native Americans, * * *. On page

20198, second paragraph under the

heading ‘‘Availability of Funds,’’ the

fourth line is amended to read: African

Americans, Native Americans, * * *.

All other information and

requirements of the April 23, 1998,

Federal Register notice remain the

same.

Dated: June 22, 1998.

Joseph R. Carter,

Acting Associate Director for Management

and Operations, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 98–17088 Filed 6–25–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Ethics Subcommittee and the Advisory

Committee to the Director, Centers for

Disease Control and Prevention:

Meetings

In accordance with section 10(a)(2) of

the Federal Advisory Committee Act

(Pub. L. 92–463), the Centers for Disease

Control and Prevention (CDC)

announces the following subcommittee

and committee meetings.

Name: Ethics Subcommittee of the

Advisory Committee to the Director, CDC.

Time and Date: 9 a.m.-3 p.m., July 16,

1998.

Place: CDC, Building 16, Room 5126, 1600

Clifton Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by

the space available. The meeting room

accommodates approximately 25 people.

Purpose: This subcommittee will

anticipate, identify, and propose solutions to

strategic and broad ethical issues facing CDC.

Matters to be Discussed: Agenda items will

include updates from the Associate Director

for Science, Dixie E. Snider, M.D., M.P.H., a

discussion on CDC’s pandemic influenza

plan, and ethical consultation on blinded

HIV serosurveys.

Name: Advisory Committee to the Director,

CDC.

Time and Date: 8:30 a.m.–3 p.m., July 17,

1998.

Place: CDC, Auditorium A, 1600 Clifton

Road, NE, Atlanta, Georgia 30333.

Status: Open to the public, limited only by

the space available.

Purpose: This committee advises the

Director, CDC, on policy issues and broad

strategies that will enable CDC, the Nation’s

prevention agency, to fulfill its mission of

promoting health and quality of life by

preventing and controlling disease, injury,

and disability. The Committee recommends

ways to incorporate prevention activities

more fully into health care. It also provides

guidance to help CDC work more effectively

with its various constituents, in both the

private and public sectors, to make

prevention a practical reality.

Matters to be Discussed: Agenda items will

include updates from CDC Acting Director,

Claire V. Broome, M.D., a report from the

Ethics Subcommittee, a discussion on

counter terrorism and the public health

infrastructure, and the agency’s prevention

research agenda.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information:

Linda Kay McGowan, Executive Secretary,

Advisory Committee to the Director, CDC,

1600 Clifton Road, NE, M/S D–24, Atlanta,

Georgia 30333, telephone 404/639–7080.

Dated: June 22, 1998.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 98–17090 Filed 6–25–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Cardiovascular and Renal Drugs

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). At least one portion of the

meeting will be closed to the public.

Name of Committee: Cardiovascular

and Renal Drugs Advisory Committee.

General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues.

Date and Time: The meeting will be

held on July 9, 1998, 9 a.m. to 5:30 p.m.,

and July 10, 1998, 9 a.m. to 12 m.

Location: National Institutes of

Health, Natcher Conference Center, 45

Center Dr., Bethesda, MD.

Contact Person: Joan C. Standaert,

Center for Drug Evaluation and Research

(HFD–110), Food and Drug

Administration, 5600 Fishers Lane,

Rockville MD 20857, 419–259–6211, or

John M. Treacy (HFD–21), 301–827–

7001, or FDA Advisory Committee

Information Line, 1–800–741–8138

(301–443–0572 in the Washington, DC

area), code 12533. Please call the

Information Line for up-to-date

information on this meeting.

Agenda: On July 9, 1998, the

committee will review new drug

application (NDA) 20–863 Pletal

(cilostazol) (Otsuka America

Pharmaceutical Inc.) to be indicated for

intermittent claudication. On July 10,

1998, the committee will discuss and

review trade secret and/or confidential

information.

Procedure: On July 9, 1998, from 9

a.m. to 5:30 p.m., the meeting is open

to the public. Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by July 2, 1998. Oral

presentations from the public will be

scheduled between approximately 9

a.m. and 10 a.m. Time allotted for each

presentation may be limited. Those

desiring to make formal oral

presentations should notify the contact

person before July 2, 1998, and submit

a brief statement of the general nature of

the evidence or arguments they wish to

present, the names and addresses of

proposed participants, and an

indication of the approximate time

requested to make their presentation.

Closed Committee Deliberations: On

July 10, 1998, 9 a.m. to 12 m., the

meeting will be closed to permit

discussion and review of trade secret

and/or confidential information (5

U.S.C. 552b(c)(4)). This portion of the

meeting will be closed to permit

discussion on pending investigational

new drug application issues.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: June 22, 1998.

Michael A. Friedman,

Deputy Commissioner for Operations.

[FR Doc. 98–17211 Filed 6–24–98; 11:16 am]

BILLING CODE 4160–01–F